ITMCTR2000002902
Not Yet Recruiting
Phase 1
Research for the mechanism of drug-drug interaction between Panax notoginseng saponins and aspirin based on the esterase enzyme and Intestinal flora
Beijing University of Chinese Medicine, Dongzhimen hospital0 sitesTBD
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Beijing University of Chinese Medicine, Dongzhimen hospital
- Status
- Not Yet Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Aged 45\-75 years;
- •2\. meet the diagnostic criteria of CHD;
- •3\. meet the diagnostic criteria of grade I–II angina according to the Canadian Cardiovascular Society (CCS);
- •4\. meet the diagnostic criteria of blood stasis;
- •5\. meet the diagnostic criteria of stable angina pectoris;
- •6\. take regular aspirin for at least one month;
- •7\. be informed of the study and voluntarily sign an informed consent.
Exclusion Criteria
- •1\. mental or physical disorders;
- •2\. pregnant, breast\-feeding, and menstruating women, as well as women planning pregnancy within three months;
- •3\. severe heart disease(acute myocardial infarction or acute myocardial infarction in six months), severe cardiopulmonary dysfunction (e.g. cardiac function II);
- •4\. severe primary diseases, such as liver and renal hematopoietic system damage, liver function (ALT\>\=2 ULN, AST\>\=2 ULN, kidney function, Cr\> 1\.0 ULN), or nervous and mental disorder;
- •5\. poorly controlled hypertension (systolic pressure \>160 mmHg; or diastolic pressure\>100mmHg);
- •6\. having participated in clinical trials in the last three months;
- •7\. underwent surgery or had hemorrhagic tendency in the last eight weeks;
- •8\. drug allergy history or with allergic constitution;
- •9\. diabetes;
- •10\. poor compliance or unsuitability for this clinical trial by investigators judgment.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not Yet Recruiting
N/A
A SEARCH TO IDENTIFY ANY DRUG-DRUG INTERACTION AMONG PSYCHIATRY INPATIENTS IN A TERTIARY HEALTHCARE CENTREHealth Condition 1: F068- Other specified mental disorders due to known physiological conditionCTRI/2022/11/047051il
Completed
N/A
Drug-drug interaction study to explore importance of CYP3A4 and OATP1B1 as factors determining pharmacokinetics of atorvastatihealthy male subjectsJPRN-UMIN000002477Clinical trial Center,Kitsato University East Hospital8
Completed
N/A
A study examining the pharmacodynamic interaction between buprenorphine and fentanylNL-OMON46809Indivior UK Ltd.22
Completed
N/A
The pharmacokinetic study of drug interaction between metformin and pyrimethamine from microdose to clinical dose in adult healthy volunteershealthy male subjectsJPRN-UMIN000002739Clinical trial Center,Kitasato University East Hospital8
Completed
Phase 1
Pharmacokinetic drug-drug interaction study between oral 300 mg netupitant/0.50 mg palonosetron fixed dose combination (Akynzeo®) and oral dexamethasone to evaluate the duration of the CYP3A4 inhibition in healthy subjectsInhibitory effect on CYP3A4Not ApplicableISRCTN93845260Helsinn Healthcare SA24